Head-to-head evidence
Iloperidone (PD psychosis use) vs Paliperidone palmitate (Invega Hafyera)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (PD psychosis use) · Fanapt
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
The trial was randomized and quadruple-blind, included both placebo and active control groups, and enrolled 593 participants. Its primary clinical symptom endpoint was PANSS-T change, with mean changes of -12.0 for iloperidone versus -7.1 for placebo, but statistical significance of the comparison is not reported, so the result remains unclear.
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Paliperidone palmitate (Invega Hafyera)
Marketed by Johnson & Johnson
NCT03345342 · Phase 3 · completed
After an open-label stabilization phase, 702 participants were randomized to six-month or three-month paliperidone palmitate and treated double-blind with matching injections, including placebo injections to preserve masking. The primary endpoint was the clinical outcome of time to relapse, but the registry reports that the median was not estimable in either group and does not provide a p-value or confidence interval, so the result cannot be classified as clearly met or missed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (PD psychosis use)'s landscape · Paliperidone palmitate (Invega Hafyera)'s landscape